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Abstract
Objective: The MAST family of microtubule-associated serine-threonine kinases (STK) have
distinct expression patterns in the developing and mature human and mouse brain. To date,
only

MAST1

has been associated with neurological disease, with

de novo

variants in

individuals with a neurodevelopmental disorder, including a mega corpus callosum.

Methods: Using exome sequencing we identify

MAST3

missense variants in individuals with

epilepsy. We also assess the effect of these variants on the ability of MAST3 to
phosphorylate the target gene product ARPP-16 in HEK293T cells.

Results: We identify

de novo

missense variants in the STK domain in 11 individuals, including

two recurrent variants p.G510S (n=5) and p.G515S (n=3). All 11 individuals had
Developmental and epileptic encephalopathy, with 8 having normal development prior to
seizure onset at < 2 years of age. All patients developed multiple seizures types, while 9/11
had seizures triggered by fever and 9/11 had drug-resistant seizures.
HEK293T cells transfected with

MAST3

In vitro

analysis of

cDNA carrying a subset of these patient-specific

missense variants demonstrated variable but generally lower expression, with concomitant
increased phosphorylation of the MAST3 target, ARPP-16, compared to wildtype. These
findings suggest the patient-specific variants may confer MAST3 gain-of-function. Moreover,
single-nuclei RNA sequencing and immunohistochemistry shows that

MAST3

expression is

restricted to excitatory neurons in the cortex late in prenatal development and postnatally.

Interpretation: In summary, we describe

MAST3

as a novel epilepsy-associated gene with a

potential gain-of-function pathogenic mechanism that may be primarily restricted to
excitatory neurons in the cortex.
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Introduction
Developmental and epileptic encephalopathies (DEEs) encompass a group of disorders
featuring frequent epileptic activity and developmental impairment. Development plateaus
or regresses when seizures are worse but can also occur independent of seizures, and are
thus attributable to the underlying cause alone

1, 2

. DEE causes can be varied, but a genetic

etiology is known or suspected in most cases without metabolic or structural causes. The
highest yield for genetic testing is in the early onset DEEs where up to 80% of patients have
a known underlying genetic etiology

3

. Both phenotypic and genetic heterogeneity are

standard features of DEEs; age of onset of seizures and developmental delay varies and
patients have a spectrum of intellectual disability severity and comorbidities. Furthermore,
an individual with one type of DEE can evolve to another, and variants in the same gene can
lead to a spectrum of DEEs

1

. In patients with DEEs, the goal of genetic investigations is not

only to end the diagnostic odyssey for families but ideally, to identify a potentially
actionable target that could lead to precision medicine therapies to help control seizures,
rescue the underlying developmental impairments, and ideally arrest further progression.
To this end, high-throughput sequencing approaches to gene discovery are an integral part
of precision medicine in epilepsy

4

.

Despite the high diagnostic rate of patients with DEEs, many patients still lack a genetic
diagnosis, likely at least in part to pathogenic variants in undiscovered genes. Here we
describe variants in

MAST3

, a microtubule-associated serine threonine kinase 3. This gene is

a member of a family of serine threonine kinases (MAST1-4 and MAST-like) that is
predominantly expressed in the human cortex, hippocampus, and striatum
MAST3 may play a role in inflammatory bowel disease

5

. Although

6

, it has not been implicated in a

neurological disorder, and its role in the brain is mostly unknown. Pathogenic variants in the

MAST3

homolog,

MAST1

, have been identified in individuals with developmental brain

abnormalities that include a particularly striking mega-corpus callosum along with cerebellar
hypoplasia and cortical malformations. Individuals also present with a spectrum of
developmental impairments including poor speech and a subset with epilepsy

7

.

As part of an international collaboration, we identified 11 individuals from 4 continents with
DEEs and

de novo

variants in the serine/threonine kinase (STK) domain of MAST3.

In vitro

modeling of a subset of these variants showed a potential gain of function effect on MAST3
kinase activity. We propose

MAST3

as a novel cause of DEEs and implicate a second member

of the MAST family in neurodevelopmental disorders though with distinct phenotypes, likely
related to gene expression timing and/or localization during neurodevelopment.

4
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Materials and Methods

Study Participants
All patients were identified by either clinical or research investigations to determine the
underlying etiology of their DEE. Patients were ascertained through personal
communication or GeneMatcher

8

. Exome sequencing was performed by a commercial

clinical laboratory in the USA or Europe (Patients 1, 2, 6, 7, 10, 11)

9

, in research

laboratories/in-house sequencing facilities (Patients 3, 4) or by exome sequencing of the
proband by the Epi25 Collaborative (Epi25 Collaborative, in press) (Patients 5, 9). The variant
of patient 8 was identified by targeted resequencing in a research laboratory using singlemolecule molecular inversion probes designed to cover the exons +5bp into the intron

10

.

Variant allele frequencies were assessed using GnomAD and TopMed (see list of URLs). All
variants were classified according to the American College of Medical Genetics and
Genomics (ACMG) guidelines for variant interpretation

11

. This study was approved by the

local institutional review board at each site and all patients and parental or legal guardians
provided consent for this study and publication of clinical and genetic data. Missense
Tolerance Ratios

12

were plotted with ggplot2, combined annotation dependent depletion

(CADD), and polyphen scores were generated by variant effect predictor. Clinical histories
were analyzed and seizure types and epilepsy syndromes were classified according to the
International League Against Epilepsy classification criteria

13

MAST3 expression in the developing human and mouse brain
MAST3
To determine the expression of

in the mature and developing human brain we

analyzed RNA-seq and single nucleus-RNA-seq data from the Allen Cell Types Database and
the Allen Developing Human Brain Database. In addition to RNA expression analysis, we
performed immunohistochemistry in 11-week-old human cerebral organoids generated
with the STEMdiff cerebral organoid kit (STEMCELL Technologies), and C57BL/6J mouse
brains (Jackson laboratory, Stock No:000664) at E14.5 and E16.5. Cerebral organoids and
mouse brains were fixed in 4% paraformaldehyde, then cryoprotected in 30% sucrose until
sunk. Samples were frozen in an ethanol/dry-ice bath and 10 to 14-micron thick sections
were cut with a cryostat (Leica). Sections were permeabilized and blocked for 1-hour at
room temperature with 0.3% Triton X-100 and 10% normal donkey serum, respectively, and
then overnight at 4ºC with the following primary antibodies: MAST3 (Novus Biologicals, Cat
# NBP1-82993), CUX1 (Santa Cruz Biotechnology, sc-514008), SATB2 (Abcam, ab51502),
TBR1 (Proteintech Group, 66564-1-Ig) and CTIP2 (Abcam, ab18465). After a 2-hour
incubation at room temperature with secondary antibodies (Donkey anti-rabbit AlexaFluor
594, anti-rat AlexaFluor 488, anti-mouse AlexaFluor 647), slides were counterstained with
Hoechst 33342 (ThermoFisher Scientific) and mounted with ProLong Gold Antifade
(ThermoFisher Scientific). Images were acquired with a Nikon A1R laser scanning confocal
microscope.

5
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Analysis of effect of MAST3 variants on phosphorylation of ARPP-16 in HEK293 cells
To assess their kinase activity, MAST3 wild-type and a subset of variants were individually
expressed in human embryonic kidney (HEK) 293T cells (ATCC CRL-3216) with the
established MAST3 substrate protein ARPP-16

14, 15

. All MAST3 constructs were cloned into

the pCMV plasmid backbone and fused to a 6x histidine tag on the C-terminus. MAST3
mutations identified in this study, as well as a kinase-dead control (K396H)

16

,were

generated by single-site mutagenesis (Agilent 210518) according to the manufacturer’s
instructions. ARPP-16 was expressed under the control of a CMV promoter and fused to a Cterminus hemagglutinin (HA) tag. HEK 293T cells (300,000/well) were plated in 12-well
plates and grown in DMEM (Thermo 11995-065) supplemented with 5% FBS and 1%
penicillin/streptomycin in a humidified incubator at 37°C and 5% CO2 one day prior to
transfection. Cells were co-transfected with 250-750 ng each of pCMV MAST3 and pCMV
ARPP-16 DNA using Lipofectamine 2000 (Invitrogen 52887) according to the manufacturer’s
instructions and incubated overnight. A pCMV GFP construct was used in place of MAST3 for
the control well expressing only ARPP-16. The next day, cells were collected in lysis buffer
(TBS + 1% Triton X-100) containing protease inhibitors (Complete Mini EDTA-Free, Roche
04693159001), briefly sonicated, and centrifuged at 14,000 x g for 5 min at 4°C.
Supernatants were transferred to a new tube and protein concentration measured using the
bicinchoninic acid (BCA) assay (Pierce 23225). Protein concentrations were adjusted to 1
ug/uL, and 15 ug was used for analysis by western blot. Samples were mixed with Laemmli
sample buffer, denatured at 98°C for 5 min, then separated by SDS-PAGE using Criterion 420% Tris-HCl gels (BioRad 3450033). Proteins were transferred to nitrocellulose membranes
and probed with HA-tag antibody (1:5000, mouse monoclonal, CST 2367S), MAST3 antibody
(1:2000, rabbit polyclonal, Bioworld BS5790), or pS46 ARPP-16 antibody (RU1102, rabbit
polyclonal, 1:3000)

14, 15

. Antibodies were diluted in 2% non-fat dry milk in TBS and

incubated overnight at 4°C. The next day, blots were incubated for 1 hour at room
temperature with IRDye 680RD goat-anti-rabbit (1:20,000, LiCor Biosciences 926-68071) and
IRDye 800CW goat-anti-mouse (1:20,000, LiCor Biosciences 926-32210). Blots were imaged
using a LiCor Odyssey system. Band signal intensities were analyzed using ImageJ software
and the pS46 ARPP-16 band intensities were normalized to the MAST3 band intensities.

Results

Genetic characterization of individuals with MAST3 variants
MAST3
Twelve individuals with variants in

were identified; 3 females and 9 males with a

median age of 10.5 years (range 7 to 44 years). 11 individuals carried variants in the Serine
Threonine kinase (STK) domain (Table 1, Fig 1A) and one outside this domain. In this study
we focus on the variants in the STK domain, all of whom exhibit DEE as described below. The
twelfth individual is a 3 year-old boy with a diagnosis of Autism Spectrum Disorder (ASD),
but with no history of seizures. He has a a similarly affected brother. We identified a
c.1963T>C, p.F655L variant (CADD = 24.3 and polyphen = 0.604) in the proband only.

6
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Language development was normal until a regression at 15-18 months leading to both
receptive and expressive language delays. Similarly, there was a regression in social
development leading to poor eye contact, smile and joint attention. Given that this variant
was associated with an atypical presentation as compared to other individuals in this cohort,
and the variant was outside of the STK domain, we interpret this variant as a variant of
uncertain significance (VUS).

Six unique missense variants were identified in 11 individuals occurring in the STK domain
and two variants were recurrent (Fig 1A): c.1528G>A, p.G510S (patients 2-6) and c.1543G>A,
p.G515S (patients 7-9). Three additional individuals had unique missense variants in the STK
domain (patient 1: c.1217G>C, p.R406P; patient 10: c.1547T>C, p.L516P; patient 11:
c.1651G>T, p.V551L).

Of the variants in the STK domain, 10/11 arose

de novo

, while segregation analysis is

pending in proband 8 with the recurrent p.G515S variant. All variants were highly conserved
(Fig 1C and D) and were predicted to be deleterious or damaging by

in silico

tools (CADD and

polyphen respectively) (Table 1) and were absent in controls (GnomAD or TOPMed).

MAST3

is intolerant to variation with a loss-of-function observed/expected upper bound fraction
(LOEUF) of 0.6 for missense variation (range 0-1 denoting intolerant to tolerant to missense
variation). Moreover, the STK domain is highly conserved and intolerant to variation, with
missense tolerance ratio (MTR) scores all below the 25

th

percentile (Fig 1B)

12

.

Epilepsy phenotype of patients with MAST3 STK domain variants
All 11 patients had DEE, including three with a Dravet-like phenotype (Table 1). All patients
had seizure onset at or before 2 years of age (median: 11 months, range: 2 to 24 months),
with 7/11 patients having seizure onset before 12 months of age. The first seizure was a
febrile convulsion, in 4 patients, an afebrile, tonic-clonic seizure in 4, myoclonic seizure in 1
and a myoclonic-atonic seizure in 1 patient (Table 1).

All patients developed multiple seizure types, including atonic (3), myoclonic (2) myoclonic
absence with eye flutter, myoclonic-atonic (1), tonic (5), generalized tonic-clonic with or
without fever (11) and focal with impaired awareness (6). Seizures evolved to include other
types in most patients, and these included atonic, myoclonic, myoclonic absence with eye
flutter, myoclonic, atonic, tonic, tonic-clonic, and focal with impaired awareness. All patients
experienced generalized tonic-clonic seizures with and without fevers (n = 11). Ten of 11
patients reported provoking factors for seizures (such as illness or fever and sleep
deprivation). Eight patients experienced episodes of convulsive status epilepticus and 3 of
non-convulsive status epilepticus.

Two patients were seizure free at their most recent follow up: patient 3, now 8 years old,
has been seizure free since age 2.5 years and is on no medications while patient 2, now

7
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seven years old, has been seizure-free since 2 years nine months on valproate alone. The
remaining 9 patients had drug-resistant seizures and were taking between 1-3 (mean: 2)
antiepileptic medication with a variety of pharmacological targets represented (Table 1); 3
patients are currently taking sodium channel blockers. Antiepileptic medications that
elicited some improvement in seizure control included valproic acid (5), topiramate (1),
zonisamide (2), phenobarbital (1), felbamate, oxcarbazepine (1), lamotrigine (1), lacosamide
(1), levetiracetam (2), briavaracetam, clobazam and cannabidiol. The ketogenic diet was
trialed in 3 patients with improvement in seizure control for patient 7 but not for patient 6
or 10.

Initial EEGs performed within 12 months of seizure onset were available for 8/11 patients; 6
were reported as normal whilst background slowing was reported in patient 1 and
generalized and focal abnormalities were reported in patient 3. Follow up EEGs were
available for 9/11 patients; 3 were reported as normal whilst 4 patients had background
disorganized or slowing, while patient 9 had bisynchronous frontal spikes and polyspikes
and patient 7 had generalized seizures with eyelid flutters captured on EEG.

Neurodevelopmental phenotype of patients with MAST3 STK pathogenic variants
Early development was normal in all 8 individuals with data available (Table 2). All
individuals except patient 5, experienced developmental regression or plateau before 2
years of age (mean: 16 months, range: 11-24 months) coinciding with seizure in 6 patients
and status epilepticus in 5. Data was unavailable for patient 5. Developmental regression
most commonly affected language (7) followed by gross motor (4), social (1), fine motor (1)
and toilet training (1). The majority of patients (10/11) are described as non-verbal or with
limited speech with expressive speech affected more than receptive speech. Eight patients
exhibited delayed gross motor milestones with walking attained at a mean age of 17.5
months (range 14-31 months). Intellectual disability was severe in 6 individuals, moderate in
3, mild-moderate in patient 9 and severe-profound in patient 10 (data not available for
patient 5).

Nine patients were normocephalic whilst patient 3 had macrocephaly and patient 9 had
microcephaly. Three of 11 patients had dysmorphic features; patients 10 and 11 had
dysmorphic facies, patient 10 also had short stature and patient 7 had 2-3

rd

toe syndactyly.

Six patients had hypotonia with patient 1 developing progressive axial hypotonia and
appendicular hypertonia. Eight patients had an abnormal gait; 5 were unsteady, had poor
balance or fell frequently, 2 had knee flexion, patient 1 uses a wheelchair and patient 9 had
wide-based walking. Sleep difficulties were reported in 7 patients, movement disorder in 2,
a high pain threshold in 2, drooling in 2, stereotypies in 2 and hypothyroidism in 2. Three
patients reported gastrointestinal difficulties including celiac disease in patient 3, cyclical
vomiting in patient 7 and gastroesophageal reflus (resolved) – in patient 11.

8
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Neuroimaging for patients with MAST3 pathogenic variants
Brain MRI was reported as normal in all patients with reports available (n=5) except for
patient 4 who had a smaller (left > right) anterior hippocampus. MR images for 5 patients
were reviewed independently by a single pediatric neuroradiologist (S.M.); all 5 were
abnormal demonstrating a small pituitary (2), thin corpus callosum (1) or both (1) (Fig 2)
Patients showed no evidence of clinical features associated with a hypo-active pituitary.

Expression of MAST3
We generated a heat map of

SCN1A/SCN3A

genes (

MAST1/MAST3

expression, as well as other epilepsy associated

), neuronal marker genes using bulk RNA-seq data from the Brainspan

atlas of the developing human brain (see list of URLs) (Fig 3A).

MAST3

expression is low over

the period of human fetal neurodevelopment, with expression increasing at 26 weeks postconception and steadily increasing postnatally (Fig 3A). Single-nuclei RNA-seq of postmortem motor cortex from the Allen Brain Map demonstrates that

MAST3

expression is

restricted to excitatory neurons in the human cortex (Fig 3B). At the protein level, MAST3 is
present in a fraction of early-born (CTIP2+) neurons, and in the majority of late-born
(CUX1+) excitatory neurons in 11-week-old human cerebral organoids (Fig 3C). In mouse
cortex, MAST3 is present in postmitotic excitatory neurons, mostly colocalizing with CTIP2
and TBR1 at E14.5, and mainly with the upper-layer neuron marker SATB2 at E16.5 (Fig 3D).

Assessment of kinase activity of MAST3 variants
MAST3
Wild-type and four of the

variants described in this study were expressed in

HEK293T cells together with its substrate, ARPP-16 (Fig 4). A kinase-dead control (p.K396H)
was also co-expressed with ARPP-16. Compared to wild-type, the expression levels of the
MAST3 variants was consistently lower, with the exception of the p.V551L variant which
exhibited intermediate expression (Fig 4A). As expected, wild-type MAST3 was active as
demonstrated by robust phosphorylation at Ser46 of ARPP-16, while there was minimal
phosphorylation by kinase-dead MAST3. Despite lower expression, the levels of Ser46
phosphorylation for each of the variants (p.G510S, p.G515S, p.L516P, p.V551L) was similar
to that of wild-type MAST3. When normalized to expression levels of MAST3 protein, the
activities of each variant was therefore higher than wild-type, reaching significance for the
p.G510S-containing mutant (*

p=

0.0159, one-way ANOVA with Dunnett’s posthoc test). The

reason for the lower expression of the MAST3 variants is not clear but could involve
decreased protein synthesis or increased protein turnover. Nevertheless, these initial
studies suggest the possibility of some sort of gain-of-function phenotype for these MAST3
variants through more effective phosphorylation of ARPP-16 and possibly other substrates.

Discussion
In this study, we describe

de novo

missense variants located in the STK domain of MAST3 as

a novel cause for DEE in 11 patients. There were two recurrent variants (p.G510S and

9
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p.G515S present in 8 individuals collectively), and an additional three variants (p.R406P,
p.L516P, p.V551L) located nearby

17

. A twelfth patient harboured a genetic change outside

of the STK domain; he did not have epilepsy but rather a diagnosis of ASD and additional
patients and functional studies are required to interpret the pathogenicity of variants
outside the STK domain. Moreover, the first variant is located within the third position of
the "Asp-Phe-Gly+1" (DFG+1) domain, which determines the specificity of the target residue
that will be phosphorylated and is highly conserved among protein kinases

17, 18

.

Modulation of MAST3 by Protein Kinase A (PKA) involves phosphorylation of position 512,
again close to the variants' location in this series

15

. Alteration of a subset of these specific

variants in the STK domain resulted in lower expression in an in vitro cell culture model, but
more effective phosphorylation of the MAST3 target, ARPP-16, consistent with a potential
gain-of-function phenotype. Notably, a gain-of-function Gly to Ser mutation (p.G2019S) is
found in an analogous position in the LRRK2 kinase and is the most common genetic cause
of Parkinson’s disease

19-21

.

Patients with pathogenic variants in the STK domain of

MAST3

typically presented with DEE,

including 3 patients with Dravet syndrome-like phenotype. All patients had seizure onset
before 2 years of age, with 7/11 having onset before 12 months of age. Most patients had
normal development prior to the onset of seizures but then experienced developmental
regression or plateau which coincided with seizure onset or episodes of status epilepticus.
All patients developed multiple seizure types: all 11 patients had generalized tonic clonic
seizures with tonic (n=5) and focal impaired awareness seizures (n=6) also common.
Triggers for seizures such as fever, illness or lack of sleep were seen in 10/11 patients. Six
patients were drug-resistant whilst 3 had achieved moderate seizure control on 2-3
antiepileptic drugs and 2 had been seizure free since age 2.5-2.75 years. All patients had
intellectual disability, with most (5/11) having severe impairment. Most patients developed
significant comorbidities include 6 patients with autism spectrum disorder or autistic
features, 8 with gait disturbances, 7 experienced sleep issues, 6 had hypotonia, 3 had
dysmorphic features and 3 had gastrointestinal problems.

MAST3 is the third of the five-member MAST family of serine/threonine kinases, which
share a STK and a postsynaptic density protein-95/discs large/zona occludens-1 domain
(PDZ)

5

. These genes have an overlapping but unique expression in the brain, with

expressed predominantly in the striatum, hippocampus, and cortex
most extensively in the rodent striatum, were the majority of

5

MAST3

. It has been studied

MAST3

expression is localized

5

to medium spine projection neurons which are inhibitory GABAergic projection neurons .
Conversely, our transcriptomic analysis illustrates that

MAST3

expression is primarily

restricted to late neurodevelopment and may be restricted to cortical excitatory neurons in
humans. This pattern contrasts to

MAST1

, which is expressed early and at high levels in the

developing brain and all cell types, including excitatory, inhibitory, and non-neuronal cells.

De novo MAST1

variants were previously described as a cause of a mega-corpus callosum

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.09.434675; this version posted March 12, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

syndrome with cerebellar hypoplasia

7

. Intriguingly, this includes a p.Gly517Ser variant

identified in three individuals, the same amino acid position as the MAST3 p.Gly510Ser
variant described in five individuals here (Fig 1D). The authors suggest

MAST1

variants result

in a dominant-negative mechanism due to reduced expression of MAST2 and MAST3
expression in a mouse model. However, here we show MAST3 variants may act in a gain-offunction manner as demonstrated by more efficient phosphorylation of its substrate, ARPP16. Therefore, another possible explanation for the reduced expression of MAST2 and
MAST3 in MAST1 knockout models is compensation for a hyperactive MAST1. Finally, the
MRI abnormalities in individuals with
with

MAST3

MAST1

pathogenic variants are extensive, while those

pathogenic variants we analyzed revealed very mild abnormalities (Fig 2). These

discrepancies likely lie in the expression patterns of the two genes, where

MAST1

is

expressed throughout development with disruption resulting in extensive malformations of
cortical development while

MAST3,

expressed later and exclusively in excitatory neurons, is

associated with DEE. This expression pattern is similar in the sodium channels, where

SCN3A

, which is expressed early in development, is associated with malformations of

cortical development; while

SCN1A

expressed much later is associated with a DEE generally

22, 23

devoid of MRI findings (Fig 3A)

. Moreover,

MAST3

expression restriction to excitatory

neurons in the cortex (but not striatum) is somewhat reminiscent of
where

SCN8A

SCN8A

-associated DEE,

is expressed in excitatory neurons, with gain-of-function variants leading to

excessive excitatory neuron activity

24

. We hypothesize that

MAST3

gain-of-function variants

may lead to the same excessive excitatory neuronal activity, though this requires further
investigation in model systems.

In both

in vitro

and

ARPP-16 at Ser46

in vivo

models of striatum, MAST3 has been shown to phosphorylate

14, 15

, and this shifts the balance of its downstream target, protein

phosphatase 2A (PP2A), from active to inactive

25

. The

in vitro

work from this study suggests

that four MAST3 variants result in a potential gain-of-function phenotype and therefore
increased phosphorylation of ARPP-16. This would suggest a decrease in PP2A activity and a
concomitant overall increase in phosphorylation of substrates for PP2A. Changes in PP2A
have been reported in individuals with intellectual disability and developmental delays, and
more specifically, the catalytic subunit of PP2A, PPP2CA (Catalytic Cα Subunit), has been
implicated in patients with language delays, hypotonia, epilepsy, and brain abnormalities
reminiscent of our patients

In summary, we propose

26

.

MAST3

as a novel gene for DEE, thereby expanding the genetic

landscape of DEEs. Patients with pathogenic

MAST3

variants present with DEE with normal

development prior to seizure onset at < 2 years. Status epilepticus and fever-sensitive
seizures are common, severe intellectual disability was seen in most as were significant
comorbidities. MAST3 is the second member of MAST family of kinases to be implicated in
CNS dysfunction. We propose a potential gain-of-function pathogenic mechanism that is
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restricted to MAST3 dysfunction in cortical excitatory neurons, reminiscent of

SCN8A

-

associated epilepsy.

URLs

:

Gene Matcher: https://genematcher.org/

gnomAD: https://gnomad.broadinstitute.org/ for both allele frequencies and LOEUF scores

TOPMed/Bravo: https://bravo.sph.umich.edu/freeze3a/hg19/

MTR: http://mtr-viewer.mdhs.unimelb.edu.au/

Brainspan atlas of the developing human brain: https://www.brainspan.org/

Allen Brain Map single-nucleus transcriptome: https://portal.brain-map.org/atlases-anddata/rnaseq/human-m1-10x
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Figure legends

MAST3

Figure 1.
patient-specific variants occur at conserved sites that are intolerant to
genetic variation (A). MAST3 patient-specific variants (number of individuals in parenthesis)
in relation to ST kinase (amino acids 367-640) and PDZ domains (amino acids 958-1038). (B)
Corresponding graph with missense tolerance ratio (MTR, y-axis) and protein position (xaxis). The tolerance ratio measures cDNA intolerance to missense variants with 5%
representing the cutoff for more intolerant segments

12

. Regions of the ST kinase domain

which are intolerant to variations portions of the ST kinase domain overlap with the
distribution of pathogenic variants. (

C) Multispecies alignment of the STK domain harboring

the MAST3 patient variants (highlighted in green) show all pathogenic variants are highly

D) Alignment of the

conserved across 11 species (identical/similar amino acids in red) (

MAST1 and MAST3 protein sequences. The serine threonine kinase (STK) domain has high
homology and the MAST1 p. G517S and MAST3 p.G510S (highlighted in green) occur at the
same position in the STK domain. Overall, these protein sequences have 61% identity.

Figure 2. MRI changes in 5 individuals with

MAST3 variants.

A-C - Sagittal FLAIR images A.

Patient 7 (p.G515S) 4 years old, normal corpus callosum and small pituitary. B. Patient 11,
15 years old, thing corpus callosum and normal pituitary. C. Patient 3, 2 years 9 months old,
thin corpus callosum and small pituitary. D. Table summarizing changes found in corpus
callosum and pituitary gland in the 5 individuals in whom we had access to MRIs. All patients
had either a thin corpus callosum and/or a small pituitary gland, but not the extensive
abnormalities observed in in individuals with

MAST3

MAST1

MAST1

pathogenic variants.

Figure 3: Expression of
and
in whole brain throughout prenatal
development and postnatally.
Heatmap of bulk RNA-seq data from the Brainspan atlas

(A)

of the developing human brain (see list of URLs).

MAST3

expression begins at about 26

weeks in prenatal development. In contrast, expression of

MAST1

is highest early in

pretnatal development (9 weeks) and then is reduced throughout the lifespan. This pattern

SCN1A

is similar in other DEE-associated genes,

and

SCN3A

associated with malformation of cortical development
markers

NESTIN, EOMES, SOX2

and

TUBB3)

, where only the latter is

23

. Key neuronal and developmental

.

are also shown FPKM = Fragments Per Kilobase

B) Heatmap of single-nucleus RNA-seq data from

of transcript per Million mapped reads. (

post-mortem adult human motor cortex for

MAST3 MAST1
MAST1
and

expressed exclusively in excitatory neurons, while

C

(see list of URLs).

MAST3

is

is expressed in both inhibitory and

excitatory neurons in the cortex. ( ) Immunofluorescence in 11-week-old cerebral organoids
shows the presence of MAST3 in a fraction of excitatory CTIP2-positive neurons (upper
panels, arrows) and in the majority of CUX1-positive neurons (lower panels, arrowheads).

(D) Immunofluorescence performed in E14.5 (left panels) and E16.5 (right panels) mouse
coronal brain sections confirm MAST3 expression in postmitotic upper layer neurons, comarkers evolving as cerebral development progresses. TBR1 and CTIP2 are neuronal
markers specific to deep cortical layers. SATB2 is a neuronal marker for upper cortical layers.
Scale bars = 50 µm.
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Figure 4. Phosphorylation of ARPP-16 at Ser46 by MAST3 kinase.

(A)

HA-tagged ARPP-16 alone, or together with MAST3, were expressed in HEK293T cells.

Cell lysates were separated by SDS-PAGE and analyzed by immunoblotting for MAST3
protein, phospho-Ser46-ARPP-16, and HA-ARPP-16. Representative blots show that WT and
all MAST3 mutant phosphorylate ARPP-16. There was minimal, background,
phosphorylation of ARPP-16, as shown by the expression of ARPP-16 alone (lane 2) or when
co-expressed with the dead-kinase mutant K396H (lane 4). Lanes: 1) GFP Only, 2) ARPP-16
Only, 3) Wild-Type MAST3 + ARPP-16, 4) K396H dead kinase control + ARPP-16, 5) G510S
MAST3 + ARPP-16, 6) G515S MAST3 + ARPP-16, 7) L516P MAST3 + ARPP-16, 8) V551L
MAST3 + ARPP-16.

(B)

Quantification of immunoblots revealed an increase in ARPP-16

phosphorylation when co-expressed with the G510S mutant compared to WT MAST3 (*

p=

0.0159, one-way ANOVA with Dunnett’s posthoc test). Note that the GFP control, ARPP-16
alone control, and the dead kinase control quantifications were omitted from the graph due
to the presence of zero values.
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Table 1 Genetic details and seizure-specific clinical features for individuals with

Inheritance
Current Age
Sex
Degree of ID
Epilepsy Diagnosis
Age at sz onset
Sz type at onset

1

2

5

6

7

8

9

10

11

chr19: g.18245432 G>A
c.1528 G>A, p.G510S
(32.0, 0.999)

chr19: g.18245432 G>A
c.1528 G>A, p.G510S
(32.0, 0.999)

chr19: g.18245432 G>A
c.1528 G>A, p.G510S
(32.0, 0.999)

chr19: g.18245432 G>A
c.1528 G>A, p.G510S
(32.0, 0.999)

chr19: g.18245432 G>A
c.1528 G>A, p.G510S
(32.0, 0.999)

chr19: g.18245447 G>A
c.1543 G>A, p.G515S
(27.3, 0.989)

chr19: g.18245447 G>A
c.1543 G>A, p.G515S
(27.3, 0.989)

chr19: g.18245447 G>A
c.1543 G>A, p.G515S
(27.3, 0.989)

chr19:g.18245451T>C
c.1547 T>C, p.L516P
(26.4, 0.999)

chr19:g.18245660G>T
c.1651G>T, p.V551L
(25.3, 0.915)

40 yr (demise)

7y 4m

8 yr 10 mo

7 yr

32 yr

9 yr

10 yr

44 yr

11 yr

13 yr

24 yr

Male

Male

Male

Female

Female

Male

Male

Male

Female

Male

Male

Severe
DEE
(Dravet syndrome-like)
18 months

Severe
DEE
(Dravet syndrome-like)
11 months

Severe

Severe

Moderate

Mild-moderate

Severe-Profound

Severe

DEE

DEE

DEE

DEE

DEE

DEE

10 months

20 months

7 months

24 months

11 months

Convulsive status
epilepticus with fever

Febrile tonic-clonic

Myoclonic

Generalized tonic clonic

24 months
Generalized tonic-clonic
(<24 hours of
vaccination)

Moderate
DEE (Myoclonic atonic
epilepsy +”)
11-12 months

Moderate

6-7 months

Severe
DEE
(Dravet syndrome-like)
2 months

Generalized tonic-clonic
in context of viral illness

Myoclonic-atonic

Tonic-clonic

Febrile convulsion

ND

Febrile convulsion

Absence (14 mo)
Atonic (Drop attacks)
(14 mo)
Tonic-clonic (14 mo)

Atonic
Tonic
TCS
Often in clusters
with fever

GTCS
Drop attacks
Absence, FIAS
Focal status

Myoclonic absence (eye
flutter)
Myoclonic atonic
Myoclonic
Atonic (head drops)
GTCS (17 mo)
Tonic (vibratory)

Tonic (20 mo)
FIAS with manual
automatisms evolving to
tonic seizure (30 years)
FBTCS

Absence (1 year)
Myoclonic
Tonic-clonic
Convulsive status
epilepticus (single event
at 7 years)

FIAS (mouth
automatism, head and
eye deviation to one side
and generalized shaking
– nocturnal)
GTC

FIAS (11 years),
myoclonic, absence,
atonic, GTCS, tonic

Drug-resistant

Drug-resistant

Moderate-control

Moderate control

Drug-resistant

Moderate-control

ND

Yes

No

No

Yes

Yes

De novo

De novo

ND
Yes (fever)

Yes (fever)

Yes

ND

ND

AED trialed
(current AED)

Current sz control
(age if applicable)
Hx nocturnal sz

4*

chr19:g.18241384G>C
c.1217G>C, p.R406P
(34.0, 1.00)

Tonic-clonic
Focal (motionless
staring, oroalimentary
automatisms, diffuse
tonic)
Absences
Often in clusters
with fever
Seizure control since age
2 y 9 mo
ND

Subsequent sz types
(age of onset if known)
(current type)
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Patient
1.Variant
(CADD, Polyphen)

MAST3 STK domain de novo variants

Atonic, tonic, GTCS;
often in clusters with
fever

Moderate-control

De novo

DEE

Well-controlled
(2.5 yrs)
No
Convulsive status d/t
VPA toxicity (Sleep
deprivation , illness)

De novo

Drug-resistant
No

De novo

TCS
Absence, FIAS

Drug-resistant at age of
last follow-up (27 yrs)
yes

De novo

De novo

Unknown

De novo

De Novo

De novo

Yes (Frequent sz with
fever)

Yes (fever)

Yes (fever)

Yes (fever, Sleep
deprivation )

No

Yes (fever)

Yes ( Sleep deprivation)

Yes (fever)

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

ND

No

Yes

No

No

Yes

No

No

No

Yes

PB, ACTH, VPA, CLB, CZP
VPA-CBZ

VPA, CBZ, LEV, PB, CLZ,
ETS
VPA

CLB, VPA, TPM
Nil

CBZ, CLB, PB, LEV

VPA, PB, PHT, CBZ, OXC,
CLP, TPM, LEV

LEV, CLB, VPA, PB, ZON,
LCS, LTG

TPM, CZP, LEV, LTG,
VPA, IVIG, DXMT, KD,
FLB, BRV, ETX Epildiolex

VPA, TPM, CBZ, PHT,
NTZ, DZP, PB

VPA, LEV, LTG

LEV, TOP, VPA, OXC, ZON

GBP, CBZ,
VPA, LCS, ZON,LEV

Effective AED

ND

ND

TPM

PB, LEV

PB+CBZ/OXC

CLB, LTG, VPA

VPA

VPA

OXC, ZNS

Ineffective AEDs
(reason )

ND

ND

ND

CBZ (status epilepticus)

ND

ND

ND

MDZ (overdose induced
absences)

LEV – irritability
TOP – GM impairment
VPA - ineffective

ND

ND

CLB (irritable, not
sleeping as well)
VPA (subacute
encephalopathy with
acquired, transient
cerebral atrophy)

ND

ND

LEV (irritability)

TPM (aggression,
delusional and
obsessional ideas)

LEV (irritability)
LTG

LEV (irritability)
TOP (GM impairment)

ND

ND

ND

No

No

No

Yes (No)

Yes (Yes)

No

No

Yes (No)

No

Continuous generalized
theta/delta slowing (18
months)

Normal (1 and 2 yrs)

Generalized and focal
features (16 months)

Normal (13 months)

Unknown

Normal (10 months)

Normal (19 months)

Unknown

Normal (13 months)

Normal (3 yrs)

ND

Mild background
slowing (6 yrs)

Background slowing,
epileptiform discharges
maximal over frontal
lobes but also from
temporal and parietal
regions (21 years)

ND

Generalized features
with mild background
slowing. Seen
generalized sz with
eyelid flutter (10 yrs)

Mildly disorganized
background (36 years)

Bisynchronous frontal
spikes and polyspikes
with other low
amplitude spikes (age
unknown)

Normal (5 yrs)

Continuous generalized
irregular theta activity
(20 years)

Provoked sz (factor)
Hx of status
epilepticus?
Hx of nonconvulsive
status?

Adverse reactions to
AEDs
Was ketogenic diet
tried? Improved sz
control?
EEG features at onset
(age)
Most recent EEG
features (age)

Normal (23mo; 6 yrs;
13yrs)

Intermittent theta/delta
slowing (7 yrs)

Normal (2 yrs 4 mo)

Epidiolex, LEV, VPA, LTG
TPM (NSCE)

TPM (lost receptive
language skills and
ability to climb stairs)
CBZ (ataxia)
CLB (behav. Issues)
ETX (vomiting)

ZNS, LCM, LEV, VPA
CBZ (breakthrough sz)
GBP (breakthrough sz)

Abbreviations: AED – antiepileptic medications, BRV – brivaracetam, CBZ – carbamazepine, CLB – clobazam, CLP – clonazepam, CBZ – carbamazepine, DXMT – dexamethasone, DZP – diazepam, ETX – ethosuximide, FLB _ felbamate, LCS – lacosamide, LTG – lamotrigine, GBP – gabapentin, IVIG –
intravenous immunoglobulin, KD – ketogenic diet, LEV – levetiracetam, LTG – lamotrigine, NTZ – nitrazepam, OXC – oxcarbazepine, PB - phenobarbital, PHT – phenytoin, TPM – topiramate, VPA – valproic acid, Sz – seizure, ZON – Zonisamide, FBTCS, focal to bilateral tonic clonic seizures, FIAS – focal
impaired awareness, GTCS – generalized tonic clonic seizures, TCS -tonic clonic seizures,, ND
* Some details of patient 4 have been published as part of a Rett phenotype screen (Iwama et al., 2019)17
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Table 2 Developmental History and Other Features for individuals with
2

3

Yes (up to 18 mo)

Yes (up to 11 mo)

Yes (up to 3 mo)

Age of regression

18 mo after seizure
onset

What domain
regressed?

Language, walking,
motor
Sat @ 4 mo
Crawled @ 9 mo
Walked @ 14 mo

Walking

Current development

Nonverbal (expressive
<< receptive).
Totally dependent for all
activities of daily living.
Severe flexion
contracture deformity.
Wheelchair user.

Current Behavioral
features

Hyperactivity, Sleep
difficulties (multiple
arousals)

Head circumference

Normal

11 mo after seizure
onset

Language
Sat @ 4 mo
Crawled @ 9 mo
Walked @ 20 mo

Non-verbal (follows
single step commands).
Totally dependent in all
activities of daily living.
Walks autonomously,
with frequent falls.

Hyperactivity,
impulsivity, and sleep
difficulties (multiple
arousals)
Normal (51,5cm,
50°centile at 2y 9 m)

Dysmorphic features

None

None

Other neurological
features
1. Tone

1. Normal until 12 yrs
then progressive axial
hypotonia and
appendicular hypertonia
2. Normal until 12 yrs,
then progressive loss of
motor skills. Wheelchair
3. High pain threshold

1. Unknown
2. Walks autonomously
but with frequent falls,
abnormal gait (right
hammertoe, shorter left
leg).

2. Gait
3. Sensory
4. Other
Movement disorder
(age of onset)

Other features

MAST3 STK domain de novo variants

1

Mild perioral dyskinesia

1. Sleep difficulties
(multiple arousals)
2. Sialorrhea
3. Intermittent fevers
(normal
immunological tests).
4. Progressive severe
flexion contracture
deformity since 12
yrs.

None

1. Sleep difficulties
(multiple arousals)

4*

Yes (up to 10 mo)

5

6

7

Yes (up to 12 months)

Uncertain

14 mo after convulsive
status

17 mo after convulsive
status

Developmental delay
prior to seizure onset

Developmental plateau
after seizure onset, and
regression following
status epilepticus at 6
years of age

Language, walking,
fine motor
Sat @ 9mo
Crawled @ 13mo
Walked @18mo

Intelligence > Gross
motor

N/A

Language

Non-verbal, not toilettrained, helps with
dressing, inconsistently
follow a single step
command, indicates
wishes by taking objects
to people or pulling
their hand, drinks from
cup and takes fork to
mouth

ASD
Macrocephaly (52cm
@17mo, >97th centile)

None

1. Slightly low tone @
20mo
2. Tremulous, falls
frequently @ 20mo

Mild ataxia early on,
normal from 3.5 years

1. Poor temperature
regulation on higher
dose of topiramate in
summer (not a problem
in winter with lower
dose)
2. Sleep difficulties
(early to sleep and
waking many times
overnight)
4. Ceoliac disease

10

11

Yes (up to 6 mo)

Uncertain

Yes (up to 7 mo)

Uncertain

Yes (up to 9-10 mo)

18 mo after convulsive
status

Developmental plateau
after seizure onset,
regression at 44 years

7 years after convulsive
status epilepticus

2 yrs (language)
5 yrs (social)

11 mo loss of language
after seizure onset

Language > Gross motor

Toilet-training at 44
years

Unknown

Language then social

Language

Sat @ 7-8mths
Walked @ 14mo

Walked @ 15 mo

Nonverbal (expressive <<
receptive) – better with
communication device,
washes hands, pulls up
pants, feeds self

Similar to an 8-10 year
old, speaks in short
sentences of <10 words,
can follow 3 commands
max, can wash and dress
himself, uses a knife and
fork, can’t manage
money or public
transport, can cook with
supervision

Speaks in some
sentences, attends
special education school

ASD, ADHD, aggression,
sleep difficulties

ASD, ADHD

Aggression, sleep
problems, autistic
features, possible ADHD

Normal (68 %ile)

Normal (63%ile)

Normal

Walked @ 2years

Nonverbal
(expressive<receptive)
Run at a trot
Pinch and scrabble
Cannot feed herself

Speaks a few words
Social emotional
development in 18-36
months range
Performal IQ: 3 yrs
Verbal IQ<3 yrs
Needs assistance with
all everyday activities

Speaks in single words
and some phrases

ASD

Impulsivity, sleep
problems

Normal (49.8cm at 6yrs
1mo)

57 cm (+1 SD; age 27
yrs; )

None

9

Sat @ 11 mo, Walked @
19 mo

Walked at 2yrs7mo

None

8
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Patient
Development ever
normal

Walked at 1 year

None

bilateral 2-3 to
sydnactyly,
rd

1. Hypotonia
2. Poor balance

Not reported

1. Hypotonia

1. Hypotonia
2. slight knee flexion, poor
toe off and bounce in gait
3. High pain threshold
4. Hand stereotopies

No

None

None

None

NA

1. Hypothyroidism
2. Atopia

1. Hypothyroidism
2. Possible mast cell
activation syndrome

1. Ophthomology –
intermittent esotropia
2. Hearing – normal
3. Language – expressive <
receptive
4. GI – cyclical vomiting
esp. after seizures
5. Sleep – poor until
started epidiolex
6. Other: bilateral 2-3rd to
sydnactyly,
Hypogammaglobulinemia,
Intermittent fevers (?)

None

Not reported

None

Nonverbal, feeds self
with hands, incontinent

Yes (details unknown)

Inattention, impulsivity,
autistic features,
agitation, disrupted
sleep pattern

Microcephaly at birth

Normal (50%ile)

Normal (50-75%tile)

None

Short stature
Prominent lower lip and
epicanthial folds
High palate, wide nasal
bridge

Midface hypoplasia,
mild prognathism,
receding anterior
hairline, thick
eyebrows, synophrys,
hypertelorism, deep set
eyes, downslanted
palpebral fissures,
narrow nasal bridge,
wide nasal ridge,
overhanging nasal tip,
short philtrum, thin
vermillion upper lip,
mildly small mouth

2. Wide-based walking

Hypotonia
1.
2.
Unsteady gait
3.
No sensory
difficulties noted
Visual impairment,
4.
abnormal
coordination

None

None

None

Nil reported

1. Sleep difficulties
2. Short stature
3. Abnormal
coordination
4. Stereotopies
5. Pica, hyperorality
6. Visual impairment
7. Difficulties with
temperature regulation
8. Abnormal
coordination

1. Scoliosis requiring
bracing, cubitus valgus,
chest wall asymmetry,
pectus carinatum, pes
planus, hallux valgus,
mildly tight Achilles
tendons
2. Resolved
gastroesophageal reflux
3. Decreased bone
density
4.
Sialorrhea

2. Hypercholesterolaemia

4. Sleep problems

16 mo

Stereotypies ,
Pica/hyperorality

1. Type 2 diabetes

3. Hypertension

Crawled at 10 mo,
walked at 21 mo
(unsteady gait)
Global developmental
impairment. Non verbal
(expressive < receptive)
- speech in 0-18 mo
range at 13 yrs, can use
a communicator to
request snack items,
some pictures or answer
questions. Assitence
with FM (feeding, self
help). Not toilet trained.

2.

Normal
1.
Flexion at hips and
knees, unsteady

ADHD- attention defecit hyperactivity disorder; ASD – autism spectrum disorder
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